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Abstract  
Aims: There is mixed evidence for an association between depression and/or anxiety (DA) and carotid 
intima-media thickness (IMT), and limited information on the related role of dyslipidaemia.  Here we 
report associations between DA and IMT in the Whitehall II cohort, considering the moderating effects 
of sex and dyslipidaemia.  
Methods: 2,822 males and 1,112 females (61±6 years) were studied during phase 7 (2002-4) of the 
Whitehall II study. IMT and lipid levels were assessed, and questionnaires (General Health 
Questionnaire [GHQ] and Centre for Epidemiologic Studies Depression Scale [CES-D]) completed. 
Linear regression was used to explore relationships between DA and IMT and the moderating effects 
of sex and dyslipidaemia. 
Results: 1,461 participants were categorised with DA. The association between DA and IMT differed 
between men and women so analyses were undertaken separately by sex. In men, IMT was significantly 
associated with dyslipidaemia (p=0.002) but not DA (p=0.29). In women, both dyslipidaemia and DA 
were independently associated with IMT (p=0.028 & p=0.031). The greatest IMT was in women with 
both DA and dyslipidaemia. These results were replicated when GHQ score was substituted for DA and 
non-HDL cholesterol for dyslipidaemia.  
Conclusions: DA is associated with increased IMT in women but not in men. Dyslipidaemia is 
associated with IMT in both men and women. Women with both DA and dyslipidaemia are potentially 
at the greatest risk of CVD.   
Word count: 223  
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Introduction 
Depression and anxiety, which have a high level of comorbidity, are associated with increased risk of 
cardiovascular disease within the general population and risk of recurrent coronary events.1-4 
However, whether these chronic stressors trigger cardiovascular events in those with underlying 
disease and/or contribute to the development of atherosclerotic disease is unclear.1-3, 5 
  
Depression and/or anxiety (DA) disorders are more prevalent in women, whereas cardiovascular 
disease (CVD) is traditionally more prevalent in men,6, 7  with conflicting associations between 
depression and CVD in men and women.8-11 
 
Increased intima-media thickness (IMT) reflects sub-clinical arterial disease and predicts clinical 
cardiovascular events.12  Both depression and anxiety have been associated with increased IMT in 
some studies but others found no association, or differing results by sex.13-18  
 
Dyslipidaemia is a key determinant of atherosclerosis and is associated with increased IMT.19 
However, the relationship between DA and dyslipidaemia is less clear.20, 21 Regardless of how DA 
influences CVD risk factors, the effects of DA on atherogenesis may be greater in those with risk 
factors (e.g.  dyslipidaemia), but have not been investigated specifically.  
 
To investigate this issue, we hypothesised that DA would be associated with carotid IMT, that this 
relationship differed by sex and would be stronger among participants with dyslipidaemia.  
 
 
Patients and methods 
Participants 
The Whitehall II cohort comprised 10,308 civil servants recruited between 1985 and 1988, 
undergoing regular follow-up. In 2002-4 (Phase 7), 4,097 participants completed questionnaires 
including questions regarding depression and anxiety symptoms and underwent assessment of 
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cardiovascular disease risk factors, disease status, body habitus and carotid artery IMT 
(Supplementary Figure 1).  The University College London Medical School committee on the ethics 
of human research provided ethical approval. 
 
Carotid intima-media thickness 
The IMT of the far wall of both common carotid arteries was measured. The mean of the two arteries 
was taken (supplement).   
 
Depression and/or anxiety 
Participants completed the General Health Questionnaire (GHQ) and the Centre for Epidemiologic 
Studies Depression Scale (CES-D) (supplement) and were categorised thereby into two groups as 
having DA or neither. Depression was defined if meeting ≥1 of the following criteria: score ≥4 on 
GHQ depression subscale; score ≥16 on the CES-D scale; prior diagnosis of depression; prescribed 
antidepressant medications.  Anxiety was defined if meeting ≥1 of the following criteria: score ≥5 on 
GHQ anxiety subscale and/or use of anxiolytic medication.  
 
Dyslipidaemia  
Fasting blood was collected for total cholesterol (TC), high density lipoprotein (HDL-C) and 
triglycerides (Trigs);  low density lipoprotein (LDL-C) was calculated using the Friedewald formula; 
non-HDL-C was calculated from TC and HDL-C22.   Participants were categorized with dyslipidaemia 
if meeting ≥1 of the following: TC >6.0, Trigs>1.7, HDL-C<1.0 and LDL-C>4.0mmol/L or receiving 
lipid lowering therapy.  Glucose, C-reactive protein (CRP) and interleukin-6 (IL-6) were also 
measured (supplement). 
 
Other covariates 
Anthropometric measures including height, weight, hip and waist measurements were taken and body 
mass index (BMI) was calculated. Seated brachial blood pressure was assessed using an automated 
Omron 907 device. 
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Statistical analysis 
In brief, right-skewed distributions were log transformed and cardiovascular risk factors compared 
between those included and excluded from the analytical sample using standard tests. The relationship 
between DA and IMT was explored using multiple regression and adjusted for cardiovascular risk 
factors. Interaction terms between DA and sex showed that the effects of DA on IMT differed 
between men and women. Subsequent analyses, therefore, were conducted separately in men and 
women. (Full details in supplement). 
 
 
Results 
The cohort consisted of 3,934 participants with complete data on IMT, GHQ score and all covariates 
(supplementary Figure 1). These participants did not differ in age from the 2,521 who were not 
included in this sample, but had a more favourable cardiovascular risk profile (Supplementary Table 
1). Study population characteristics are shown by sex in Table 1 (combined in Supplementary Table 
1).  
 
Relationship between depression and/or anxiety and IMT 
1,461(37%) participants (937 [33%] men and 524 [47%] women) were categorised with DA.  
IMT was correlated with all risk factors, whereas DA was negatively correlated with age, systolic 
blood pressure and IMT (Supplementary Table 2).   
 
In men and women combined, unadjusted analysis showed IMT was negatively associated with DA 
(Cohen’s D=-0.09, p=0.006). However, adjustment for cardiovascular risk factors removed this 
association (p=0.96). Inclusion of the interaction variable “DA by sex” demonstrated that the 
association of DA with IMT differed between men and women (sex*DA interaction, p=0.016). 
Therefore, further analyses were conducted separately for men and women. Adjustment for the 
presence of dyslipidaemia confirmed the sex differences in the relationship between DA and IMT 
(Table 2). 
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In men, there was an association between dyslipidaemia and IMT (Cohen’s D=0.12, p=0.002), but no 
association between DA and IMT (p=0.27) plus no interaction between dyslipidaemia and DA on 
IMT (p=0.50).  
 
However, in women there were independent associations between IMT and both dyslipidaemia 
(Cohen’s D=0.14, p=0.028) and DA (Cohen’s D=0.13, p=0.031), but no evidence of an interaction 
between dyslipidaemia and DA on IMT (p=0.15). Thus, women with both DA and dyslipidaemia 
have greater IMT than those in other categories (Figure 1). Further adjustment for use of 
antihypertensive medication did not affect these findings (data not shown). The associations between 
DA and IMT were unaffected following sensitivity analysis using a more extreme cut-off for anxiety 
(Supplementary Table 5). When the DA group was separated into D only, A only and D+A, there was 
no overall difference in IMT for either men or women (supplementary Table 3). However, women 
with D+A had greater IMT than those with neither (Cohen’s D=0.17 p=0.047). This was replicated in 
the sensitivity analysis using a greater threshold for anxiety and resulted in greater separation in IMT 
between those with D+A versus neither (Cohen’s D=0.22 p=0.025) (Supplementary Table 5). 
 
We also explored the relationship between non-HDL-C, DA and sex (excluding those on lipid 
lowering therapy). The association between DA and IMT still differed by sex (DA by sex interaction, 
Cohen’s D=0.19, p=0.013), therefore, the association between DA and non-HDL-C was examined 
separately in men and women.  
 
Furthermore, consideration of non-HDL-C confirmed the differences in the effect of DA on IMT 
between the sexes (Table 2). In men, there was a strong positive association between non-HDL-C and 
IMT (Cohen’s D=0.22, p<0.001), but no association between DA and IMT (p=0.32). There was no 
evidence for an interaction effect between non-HDL-C and DA on IMT (p=0.93). In women, both 
non-HDL-C (Cohen’s D=0.20, p=0.016) and DA (Cohen’s D=0.14, p=0.025) were independently 
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associated with IMT with no interaction (p=0.70). Thus, women with both DA and high non-HDL-C 
have greater IMT than those in other categories (as for women with DA and dyslipidaemia). 
 
Relationship between GHQ score and IMT  
GHQ score was higher in women than men (Cohen’s D=0.17, p<0.001), positively correlated with 
BMI, and negatively correlated with age, systolic and diastolic blood pressure and IMT 
(Supplementary Table 4). However, following adjustment for major cardiovascular risk factors, this 
association between GHQ score and IMT disappeared (p=0.33).  The addition of an interaction term 
between sex and GHQ score again showed that the association of GHQ score with IMT differed 
between men and women (Cohen’s D=0.07, p=0.05). The results mirrored those with DA such that, in 
women, both dyslipidaemia (Cohen’s D=0.14, p=0.024) and GHQ score (Cohen’s D=0.08, p=0.010) 
were independently associated with IMT, but without interaction (p=0.82). In men, dyslipidaemia 
(Cohen’s D=0.13, p=0.002), but not GHQ score (p=0.93), was associated with IMT and there was no 
interaction (p=0.31).  
 
Discussion 
Our principal findings are finding that women with both DA and dyslipidaemia have greater IMT than 
women within the other categories. Sex had a moderating effect on the relationship between DA and 
IMT: women with DA were more likely to have greater IMT than those without DA, but no such 
relationship is seen in men.  
 
Sex differences in the associations of depression and/or anxiety with IMT    
Our finding of a moderating effect of sex on the association between DA and IMT with higher IMT in 
women with DA agrees with previous work.17, 23 However, studies tended to consider depression or 
anxiety individually, despite co-morbidity between the two conditions. In a middle-aged Korean 
cohort, females with depressive symptoms had greater IMT, but there was no such difference in 
males.17 In contrast, in a Hispanic cohort, a moderating effect of sex on IMT in depression was only 
found in males.16  The reasons for these differences are unclear, but neurological influences may 
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contribute. Women appear to have greater amygdala activity in response to negative emotion, linked 
to greater prevalence of depression.24 A small study found that greater amygdala activity, in response 
to behaviourally relevant stimuli, is associated with increased IMT.25 Loss of the protective effect of 
oestrogen in postmenopausal women may also contribute as IMT progression accelerates beyond the 
age of 50,26 as may methodological differences in the assessment of cIMT and DA symptoms.16, 17 
Furthermore, depression develops earlier in women, potentially extending exposure promoting 
subclinical atherogenesis.27 
 
Dyslipidaemia, depression and/or anxiety 
The observation that women with DA who also have dyslipidaemia had greater IMT is particularly 
interesting.  Although differences between the groups were small, the adjusted effect of DA on IMT 
in women is similar in magnitude to that of dyslipidaemia in both sexes (according to both absolute 
and Cohen’s D values). Thus, the cumulative combined effect on the arteries could have a clinically 
significant impact over time, as seen in both the healthy population and those with pre-existing 
coronary disease.1, 2, 20, 21  Our findings identify a group  of older women with high lipid levels and DA 
symptoms, that are potentially at greater risk of future cardiovascular events.  Analyses categorising 
the participants into the separate depression, anxiety or depression and anxiety indicated that both 
groups with depression had greater IMT, but it was only the combined group where this difference 
was significant when compared with those without either depression or anxiety. However, 
diminishing numbers in these subgroups limits analysis power. 
 
Our study explored a prespecified hypothesis that the presence of dyslipidaemia, itself associated with 
subclinical vascular pathophysiology and worse cardiovascular outcome,19, 28, 29 would be associated 
with DA and arterial disease. Patients with depression or anxiety have been shown to have increased 
lipid levels and increased risk of cardiovascular disease1, 2, 21  and  patients with more severe 
symptoms of DA are more prone to dyslipidaemia alongside obesity.20  Notably, we found the 
relationship between dyslipidaemia and IMT remained after adjustment for obesity measures.  The 
combination of depression and dyslipidaemia resulting in the greatest IMT in these women may be 
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due to a mixture of lifestyle factors, and biological mechanisms such as inflammation (although we 
found no evidence of a further interaction between DA and CRP or IL6 [data not shown]), as well as 
other possible psychophysiological influences on lipid metabolism. 
 
Little previous work has explored the impact of specific cardiovascular risk factors on the relationship 
between DA and subclinical vascular pathophysiology. Violanti et al found an association between 
depressive symptoms and IMT but only in those without hypertension.30 Wagner et al found that type 
2 diabetes had no impact on the association between lifetime history of depression and impaired 
endothelial function.31 Therefore, the finding that women with DA and dyslipidaemia have greater 
IMT, may have important clinical implications, suggesting that there may be a particular benefit in 
treating dyslipidaemia in women with DA.  Our findings confirm the importance of dyslipidaemia in 
men but suggest no incremental impact of DA on atherogenesis. We hypothesised that dyslipidaemia 
would be associated with subclinical arterial disease (cIMT) in DA in our prespecified analysis plan, 
rather than undertaking a “hypothesis-generating” exploratory analysis of multiple primary risk 
factors of interest (e.g. smoking, hypertension, diabetes, inflammation), but fully adjusted for these 
parameters in our multivariable analyses.   
 
Potential mechanisms 
A number of potential mechanisms may mediate the risk of cardiovascular disease in 
depression/anxiety, including increased hypothalamic-pituitary-adrenal axis activity (HPA) and 
inflammation, which promote cardiovascular and platelet dysfunction.32-34  
 
Lifestyle behaviours including cigarette smoking, lower physical activity and poor diet are all 
associated with common mental disorders and increased cardiovascular risk3, 35 through creation of an 
atherogenic vascular milieu. Although we adjusted for socioeconomic status, smoking and obesity, 
other less well-characterised “lifestyle”-related factors may have contributed. 
 
Limitations  
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IMT was only assessed during Phase 7 of the WHII study.  Therefore, we were only able to explore 
cross-sectional but not prospective relationships between DA and IMT. The depression group is a 
composite of participants, including those with symptoms meeting depression ‘cut-offs’, those 
previously diagnosed as depressed and those taking anti-depressant medication.  Thus, a wide range 
of symptom severity from mild- to severe clinical- depression, may have differing relationships with 
the vascular measures.  Not all participants would have currently been undergoing a depressive 
episode, as participants previously diagnosed with depression were included in the depression group.  
Equally, both the GHQ and CES-D questionnaires only concern recent symptoms and so may miss 
those participants who have previously had a biologically relevant period of DA. This study also 
could not discriminate single or recurrent episodes of DA. These limitations also apply to some extent 
to those with anxiety.  
 
DA was examined as a combined variable due to the considerable overlap in conditions. However, we 
did consider depression and anxiety conditions separately and combined but found no overall 
differences in IMT between the four symptom groups. Whether these tools for identifying DA 
symptoms are sensitive enough to fully disentangle A from D is uncertain. Furthermore, splitting the 
analysis by gender and DA category reduces the group size considerably and we cannot be sure that 
the study was sufficiently powered to assess the separate effect of D and A. A larger prospective 
cohort would be required. Despite this, most of the associations described in women have small effect 
sizes, below or close to 0.2 as indicated by Cohen’s D measure of the standardised effect (albeit 
similar in magnitude to the relationship between dsylipidaemia and IMT in men). Confirmatory 
findings from other studies are needed before these results could be generalised. 
 
Only a small proportion of those classified with DA were taking psychotropic medication, similar to 
prior observations in EUROASPIRE cardiac patients.36 This may partly be due to our only assessing 
current, but not prior, symptoms and use of psychotropic medication; plus a large proportion of those 
with DA were likely to subclinical or mild symptomology. There may also have been a reluctance to 
declare psychotropic medication use due to perceived stigma. 
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As this was a relatively healthy population, the dyslipidaemia definition was quite broad, therefore 
participants meeting the criteria did not necessarily have severe dyslipidaemia. The lipid cut-offs were 
based on European Guidelines and associated with increased cardiovascular risk.37 Using more 
stringent lipid levels would reduce sample size, with consequent loss of power. However, similar 
relationships were observed when restricting the analysis to non-HDL-C.   
 
Conclusion 
In conclusion, we found that women with DA and dyslipidaemia have increased IMT. Regardless of 
the presence or absence of dyslipidaemia, DA did not have a significant effect on IMT in men.  
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Table 1: Participant characteristics of the whole population and divided by sex. 
  
Mean ± Standard deviation / 
Percentage (N) 
  
 Men  
(n=2822) 
Women  
(n=1112) 
Age (yrs)  61.1 ± 5.8 60.9 ± 5.9 
Waist circumference (cm)  93.7 ± 10.4 82.8 ± 12.4 
Body mass index (kg/m2)  26.4 ± 3.7 26.7 ± 5.1 
Low employment grade  3.5% (99) 26.5% (295) 
Current smokers    6.2% (174) 8.4% (92) 
Antidepressants   2.5% (69) 4.4% (49) 
Anxiolytics  0.3% (8) 0.4% (4) 
Lipid lowering therapy   12.0% (337) 9.1% (101) 
Antihypertensive therapy  22.6% (637) 23.7% (263) 
Systolic blood pressure (mmHg)  127.4 ± 15.4 125.2 ± 173 
Diastolic blood pressure (mmHg)  74.2 ± 10.2 72.5 ± 10.4 
Heart rate (bpm)  66.6 ± 11.6 67.8 ± 9.7 
Fasting glucosea (mmol/L)  5.43 ± 0.16 5.20 ± 0.15 
Total cholesterol (mmol/L)  5.63 ± 0.99 5.92 ± 1.01 
HDL-cholesterol (mmol/L)  1.48 ± 0.39 1.82 ± 0.49 
Triglycerides (mmol/L)  1.41 ± 0.90 1.21 ± 0.68 
LDL-cholesterol (mmol/L)  3.51 ± 0.91 3.54 ± 0.96 
NonHDL-cholesterol (mmol/L)  4.15 ± 1.01 4.09 ± 1.06 
Dyslipidaemia   60% (1692) 58% (647) 
C-reactive proteina (mg/L)  1.21 ± 1.06 1.43 ± 1.13 
Interleukin 6a (pg/ml)  1.88 ± 0.57 1.75 ± 0.56 
Depression and/or anxiety   33% (937) 47% (524) 
General health questionnaire scoreb  2.59 ± 5.13 3.34 ± 5.80 
Intima-media thickness (mm)  0.80 ± 0.16 0.77 ± 0.14 
 
HDL = high density lipoprotein, LDL = low density lipoprotein  
a Estimates shown for fasting glucose, C-reactive protein and interleukin 6 are the geometric mean ± 
standard deviation of the logged values. 
b Estimates shown are for untransformed GHQ. Log(GHQ+1.0) transformation used in all other 
analyses. 
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Table 2. Association between IMT and, (A) depression and/or anxiety and dyslipidaemia, and (B) 
depression and/or anxiety and non-HDL, separately in men and women 
 Men  Women 
 N Mean IMTa (95%CI)  N Mean IMTa (95%CI) 
Analysis A      
Depression and/or anxiety      
           No 1885 0.798 (0.790, 0.805)  588 0.766 (0.755, 0.776) 
           Yes 937 0.791 (0.781, 0.801)  524 0.782 (0.771, 0.793) 
                p-value  0.27   0.031 
      
Dyslipidaemia      
           No 1130 0.785 (0.775, 0.794)  465 0.765 (0.753, 0.777) 
           Yes 1692 0.803 (0.796, 0.811)  647 0.783 (0.773, 0.793) 
                p-value  0.002   0.028 
      
Analysis B      
Depression and/or anxiety      
           No 1671 0.794 (0.786, 0.801)  536 0.764 (0.753, 0.775) 
           Yes 814 0.787 (0.777, 0.797)  475 0.782 (0.771, 0.794) 
                p-value  0.32   0.025 
      
Non-HDL       
    Lowest third (≤ 3.6) 642 0.776 (0.764, 0.788)  340 0.761 (0.748, 0.775) 
    Middle third (3.7 – 4.5) 945 0.788 (0.778, 0.797)  337 0.771 (0.757, 0.785) 
    Highest third (> 4.5) 898 0.808 (0.798, 0.818)  334 0.786 (0.772, 0.801) 
                p-value (trend)  <0.001   0.016 
 
a Associations of depression and/or anxiety and dyslipidaemia (Analysis A) and of depression and/or 
anxiety and non-HDL (Analysis B), are mutually adjusted. All analyses are also adjusted for age, 
systolic blood pressure, waist circumference, body mass index, fasting glucose, c-reactive protein, 
interleukin-6, smoking status and socio-economic status.  
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Figure 1: IMT in women with and without DA and dyslipidaemia. IMT is adjusted for age, systolic blood 
pressure, waist circumference, body mass index, fasting glucose, c-reactive protein, interleukin-6, 
smoking status and socio-economic status (Bars show standard errors of the means). 
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Supplementary information: 
 
Supplementary methods 
 
Participants completed the 30-item General Health Questionnaire (GHQ) and the Centre for 
Epidemiologic Studies Depression Scale (CES-D)1, 2. The GHQ focuses on self-reported symptoms of 
anxiety, depression and associated psychosocial dysfunction. Within each question, the participant 
confirms whether or not a specific symptom is present. The scores were then summed, with a higher 
score reflecting more severe symptoms of common mental disorders. In addition, subscales were 
identified for depression and anxiety using factor analysis.  Based on previous studies, depression was 
defined as having a score of ≥4 on the depression subscale, and anxiety was identified as having a 
score of ≥5 of the anxiety subscale3, 4. The depression subscale has a Cronbach α of =0.88 and a retest 
correlation of r=0.78 and the anxiety subscale has a Cronbach α of =0.86. Using the CES-D scale, 
clinically significant depression symptoms were defined by a score of ≥16.  Participants had also been 
questioned about prior clinical diagnoses of depression and use of anti-depressant and anxiolytic 
medications.  
 
Carotid intima-media thickness. 
Participants rested in a supine position, the right and left common carotid arteries were imaged using 
an ALOKA Prosound 5500 ultrasound machine.  Longitudinal images of the common carotid artery 
approximately 1 cm proximal to the bifurcation, with a clearly defined far wall intima-media 
complex, were zoomed and triggered to the R-wave of the ECG and recorded for later analysis. 
 
IMT was measured as the distance between the leading edge of the intima and the media-adventitia 
border using callipers integral to the ultrasound machine.  Three measurements, each from a separate 
frame, were taken from the left and right arteries; mean IMT was calculated from the combined 
results. 
 
 
2 
 
 
Measurement of inflammatory markers. 
Interleukin-6 (IL-6) and c-reactive protein (CRP) were measured in the serum stored at -70OC until 
analysis. CRP was assessed using a high sensitivity immunonephelometric assay in a BN ProSpec 
nephelometer (Dade Behring, Milton Keynes, UK). Values lower than the detection limit (0.154 mg/l) 
were assigned a value equal to half the detection limit. For assessment of short term biological 
variation and laboratory error a repeated sample was taken from 533 participants. Intra- and inter-
assay coefficients of variation were 4.7% and 8.3%. Reliability between samples was assessed with 
Pearson’s r correlation coefficients: r =0.72 
IL-6 was assessed using a high-sensitivity enzyme linked immunosorbent assay (ELISA) (R&D 
systems, Oxford, UK). Values lower than the detection limit (0.08pg/ml) were assigned a values equal 
to half the detection limit. For assessment of biological variation and laboratory error, a repeated 
sample was taken from 329 participants at phase. Intra and inter-assay coefficients of variation were 
7.5% and 8.9%. Reliability between samples was assessed with Pearson’s r coefficients: r = 0.63. 
Statistical analysis 
The distributions of fasting glucose, CRP and IL-6 were right-skewed and log transformed for 
analysis. Similarly, GHQ score, range 0 to 30, was log transformed after the addition of one to 
produce a more normally distributed variable. Cardiovascular risk factors were compared between 
those included and not included in the final analytic sample using independent t-tests, independent 
Mann Whitney U tests or Chi square tests, where appropriate. Pearson and Spearman correlations 
were used to compare associations between cardiovascular risk factors and IMT, DA classification 
and GHQ score.   
 
Linear regression was used to explore the relationship between DA and IMT and Cohen’s D used to 
show the standardised effect. The initial regression model was unadjusted while the second model 
included the following cardiovascular risk factors: age, systolic blood pressure (SBP), TC, fasting 
3 
 
glucose, waist, BMI, CRP, IL-6, smoking and socio-economic status (defined as last known 
employment grade). To investigate the moderating effects of sex on the relationship between IMT and 
DA, a sex by DA interaction term was added to this model. Since this indicated that the relationship 
between DA and IMT differed in men and women, further models examining the confounding and 
moderating effects of dyslipidaemia and non-HDL were fitted in men and women separately. 
Associations between IMT and non-HDL were assessed using tests for trend across the non-HDL 
categories and the magnitude of these associations was described using Cohen’s D comparing the 
highest versus lowest third of non-HDL.  
 
Analyses were repeated, replacing DA with the GHQ score, as a continuous variable as an indicator of 
DA. 
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Supplementary Table 1: Characteristics of 6455 participants who completed the Phase 7 
questionnaire and screening in 2002-04 according to whether they are in the analytic sample 
 
 
HDL = high density lipoprotein, LDL = low density lipoprotein  
a Estimates shown for fasting glucose, C-reactive protein and interleukin 6 are the geometric mean ± 
standard deviation of the logged values. 
b Estimates shown are for untransformed GHQ. Log(GHQ+1.0) transformation used in all other 
analyses.
 Study sample 
p-value  Not in sample  In sample 
 Mean ± SD or % (n) Mean ± SD or % (n) 
Number 2521 3934  
Age (yrs) 61.2 ± 6.1 61.1 ± 5.9 0.52 
Female, % 30.6% (771) 28.3% (1112) 0.049 
Waist circumference (cm) 92.5 ± 12.8 90.6 ± 12.0 <0.001 
Body mass index (kg/m2) 27.2 ± 4.7 26.5 ± 4.2 <0.001 
Low employment grade  12.0% (299) 10.0% (394) 0.014 
Current smokers 10.2% (255) 6.8% (266) <0.001 
Antidepressants 4.6% (115) 3.0% (118) 0.001 
Anxiolytics 0.7% (18) 0.3% (12) 0.030 
Lipid lowering therapy 12.4% (313) 11.1% (438)  0.12 
Antihypertensive therapy 27.2% (683) 22.9% (900) <0.001 
Systolic blood pressure (mmHg) 130.6 ± 18.0 126.8 ± 16.0 <0.001 
Diastolic blood pressure (mmHg) 75.7 ± 10.7 73.7 ± 10.3 <0.001 
Heart rate (bpm) 69.1 ± 11.7 67.0 ± 11.1 <0.001 
Fasting glucosea (mmol/L) 5.41 ± 0.19 5.36 ± 0.16 0.04 
Total cholesterol (mmol/L) 5.75 ± 1.07 5.71 ± 1.01 0.10 
HDL-cholesterol (mmol/L) 1.58 ± 0.46 1.58 ± 0.44 0.95 
Triglycerides (mmol/L) 1.47 ± 1.05 1.35 ± 0.85 <0.001 
LDL-cholesterol (mmol/L) 3.52 ± 0.96 3.52 ± 0.92 0.96 
Non-HDL-cholesterol (mmol/L) 4.17 ± 1.07 4.13 ± 1.03 0.11 
Dyslipidaemia 62% (1551) 59% (2339) 0.094 
C-reactive proteina (mg/L) 1.45 ± 1.13 1.27 ± 1.09 <0.001 
Interleukin 6a (pg/ml) 2.10 ± 0.67 1.84 ± 0.58 <0.001 
Depression and/or anxiety  42% (1066) 37% (1461) <0.001 
General health questionnaire scoreb 3.30 ± 5.77 2.80 ± 5.34 <0.001 
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Supplementary Table 2: Pearson correlations of cardiovascular risk factors with intima-media 
thickness and depression and/or anxiety grouping.  
  
 Intima-media thickness 
(N=3934) 
  Depression and/or anxiety 
(N=3934) 
  Correlation p-value   Correlation p-value 
Age (yrs) 0.307 <0.001   -0.124 <0.001 
Waist circumference (cm) 0.132 <0.001   -0.035 0.027 
Body mass index (kg/m2) 0.090 <0.001   0.026 0.10 
Systolic blood pressure (mmHg) 0.225 <0.001   -0.056 <0.001 
Diastolic blood pressure (mmHg) 0.067 <0.001   -0.033 0.039 
Heart rate (bpm) -0.062 0.001   0.025 0.19 
Fasting glucosea (mmol/L) 0.089 <0.001   -0.015 0.35 
Total cholesterol (mmol/L) 0.047 0.003   -0.009 0.58 
HDL-cholesterol (mmol/L) -0.069 <0.001   0.001 0.93 
Triglycerides (mmol/L) 0.026 0.010   0.026 0.11 
LDL-cholesterol (mmol/L) 0.071 <0.001   -0.015 0.35 
NonHDL-cholesterol (mmol/L) 0.076 <0.001   -0.009 0.56 
C-reactive proteina (mg/L) 0.091 <0.001   0.013 0.43 
Interleukin 6a (pg/ml) 0.107 <0.001   -0.003 0.84 
Intima-media thickness (mm) -      -0.044 0.006 
 
HDL = high density lipoprotein, LDL = low density lipoprotein  
a Logged values for fasting glucose, C-reactive protein and interleukin 6 are used in the analyses. 
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Supplementary Table 3: Association between IMT and depression and/or anxiety and dyslipidaemia, 
separately in men and women 
 Men  Women 
 N Mean IMTa (95%CI)  N Mean IMTa (95%CI) 
      
Depression and/or anxiety      
           Neither 1885 0.798 (0.790, 0.805)  588 0.766 (0.755, 0.776) 
           Anxiety only 431 0.793 (0.779, 0.808)  212 0.776 (0.759, 0.793) 
           Depression only 220 0.798 (0.777, 0.818)  120 0.786 (0.764, 0.809) 
           Depression and anxiety 286 0.781 (0.763, 0.799)  192 0.787 (0.769, 0.805) 
                p-value  0.40   0.13 
      
Dyslipidaemia      
           No 1130 0.783 (0.772, 0.793)  465 0.770 (0.757, 0.783) 
           Yes 1692 0.802 (0.793, 0.811)  647 0.787 (0.777, 0.798) 
                p-value  0.002   0.027 
      
      
 
a Associations of depression and/or anxiety and dyslipidaemia are mutually adjusted. All analyses are 
also adjusted for age, systolic blood pressure, waist circumference, body mass index, fasting glucose, 
c-reactive protein, interleukin-6, smoking status and socio-economic status.  
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Supplementary Table 4: Spearman correlation coefficients between cardiovascular risk factors and 
GHQ score. 
  
  GHQ score 
  Correlation p-value 
Age (yrs) -0.152 <0.001 
Waist circumference (cm) 0.017 0.30 
Body mass index (kg/m2) 0.058 <0.001 
Systolic blood pressure (mmHg) -0.065 <0.001 
Diastolic blood pressure (mmHg) -0.022 0.18 
Heart rate (bpm) 0.032 0.087 
Fasting glucose (mmol/L) -0.018 0.26 
Total cholesterol (mmol/L) -0.018 0.27 
HDL-cholesterol (mmol/L) -0.027 0.089 
Triglycerides (mmol/L) 0.030 0.056 
LDL-cholesterol (mmol/L) -0.007 0.66 
Non-HDL-cholesterol (mmol/L) 0.000 0.99 
C-reactive protein (mg/L) 0.031 0.052 
Interleukin 6 (pg/ml) 0.033 0.004 
Intima-media thickness (mm) -0.035 0.030 
 
HDL = high density lipoprotein, LDL = low density lipoprotein  
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Supplementary Table 5: Sensitivity analysis of the association between IMT and depression and/or 
anxiety using a more extreme cut off for anxietya, separately in men and women 
 
 Men  Women 
 N Mean IMTb (95%CI)  N Mean IMTb (95%CI) 
      
Depression and/or anxiety      
           Neither 2108 0.797 (0.790, 0.803)  696 0.766 (0.756, 0.775) 
           Depression and/or anxiety 714 0.791 (0.779, 0.802)  416 0.786 (0.774, 0.798) 
                p-value  0.37   0.027 
      
Depression and/or anxiety      
           Neither 2108 0.797 (0.790, 0.803)  696 0.766 (0.756, 0.775) 
           Anxiety only 208 0.796 (0.775, 0.817)  104 0.785 (0.760, 0.809) 
           Depression only 314 0.794 (0.777, 0.811)  180 0.781 (0.763, 0.801) 
           Depression and anxiety 192 0.780 (0.758, 0.802)  132 0.793 (0.771, 0.815) 
                p-value  0.53   0.067 
      
 
a Sensitivity analysis uses cut off of ≥6 for anxiety score, so prevalence of anxiety = 16%. 
b All analyses are also adjusted for age, dyslipidaemia, systolic blood pressure, waist circumference, 
body mass index, fasting glucose, c-reactive protein, interleukin-6, smoking status and socio-
economic status.  
 
  
9 
 
Supplementary Table 6: Association between IMT and depression and/or anxiety and non-HDL, 
separately in men and women 
 Men  Women 
 N Mean IMTa (95%CI)  N Mean IMTa (95%CI) 
      
Depression and/or anxiety      
           Neither 1671 0.794 (0.786, 0.801)  536 0.763 (0.753, 0.774) 
           Anxiety only 383 0.790 (0.774, 0.805)  189 0.774 (0.756, 0.793) 
           Depression only 191 0.789 (0.768, 0.810)  113 0.784 (0.761, 0.808) 
           Depression and anxiety 240 0.781 (0.762, 0.800)  173 0.789 (0.770, 0.808) 
                p-value  0.67   0.11 
      
Non-HDL       
    Lowest third (≤ 3.6) 642 0.774 (0.761, 0.787)  340 0.767 (0.752, 0.781) 
    Middle third (3.7 – 4.5) 945 0.785 (0.774, 0.797)  337 0.776 (0.761, 0.790) 
    Highest third (> 4.5) 898 0.806 (0.794, 0.817)  334 0.791 (0.776, 0.806) 
                p-value (trend)  <0.001   0.018 
      
 
a Associations of depression and/or anxiety and dyslipidaemia are mutually adjusted. All analyses are 
also adjusted for age, systolic blood pressure, waist circumference, body mass index, fasting glucose, 
c-reactive protein, interleukin-6, smoking status and socio-economic status.  
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Supplementary Figure 1: Cohort flowchart 
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